<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03596619</url>
  </required_header>
  <id_info>
    <org_study_id>2018-05</org_study_id>
    <nct_id>NCT03596619</nct_id>
  </id_info>
  <brief_title>The Study of Plum-blossom Needling Enhancing Efficacy of Aminolevulinic Acid-photodynamic Therapy for Actinic Keratosis</brief_title>
  <official_title>The Study of Plum-blossom Needling Enhancing Efficacy of Aminolevulinic Acid-photodynamic Therapy for Actinic Keratosis: a Randomized and Multi-center Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Dermatology Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Central South University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan No.1 Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tripler Army Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Affiliated Hospital of Xi'an Jiaotong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Henan Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Dermatology Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background Limited in the depth of absorption and penetration of photosensitizers, ALA-PDT
      treatment is not strong enough for thickening significantly AK lesions. Pre-study has proved
      that plum-blossom needling facilitates delivery of topical ALA into the dermis. It could help
      ALA to diffuse a little more broadly in superficial dermis and obtain similar clinical effect
      with a much lower cost.

      Objective We sought to investigate whether plum-blossom needling (PBN) would enhance the
      efficacy of ALA-PDT for AKs.

      Methods Two hundred and fifty patients, previously diagnosed as having AKs of the face and
      scalp, were randomized distribution into two groups. The PBN-ALA-PDT group underwent vertical
      skin tapping with PBN before applying 10% ALA cream and narrow-band light-emitting diode
      (LED) irradiation (mean 633 nm, with a standard deviation [SD] of 10 nm; 100-200 J/cm2). The
      ALA-PDT group received ALA cream and irradiation only. During the next 1 year period of
      follow up, patients were clinically evaluated for new AKs.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 30, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The clearance rate of Actinic Keratoses</measure>
    <time_frame>two weeks after first session</time_frame>
    <description>The change rate in lesion clearance of Actinic Keratoses at two weeks after the first session will be measured as the primary outcome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment sessions</measure>
    <time_frame>two weeks after the last session</time_frame>
    <description>Number of treatment sessions required for clinical cure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of new Actinic Keratoses</measure>
    <time_frame>1, 3, 12 months after last session</time_frame>
    <description>The change in number of actinic keratoses at each follow-up will be measured as the second outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>1, 3, 12 months after last session</time_frame>
    <description>Measurement of crusting, erythema, edema, pain and et al.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Actinic Keratoses</condition>
  <arm_group>
    <arm_group_label>PBN-ALA-PDT Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The PBN-ALA-PDT group underwent vertical skin tapping with PBN before applying 10% ALA cream and narrow-band light-emitting diode (LED) irradiation (mean 633 nm, with a standard deviation [SD] of 10 nm; 100-200 J/cm2).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ALA-PDT Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The ALA-PDT group received ALA cream and irradiation only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PBN</intervention_name>
    <description>The PBN-ALA-PDT group underwent vertical skin tapping with PBN before applying 10% ALA cream and narrow-band light-emitting diode (LED) irradiation (mean 633 nm, with a standard deviation [SD] of 10 nm; 100-200 J/cm2). The ALA-PDT group received ALA cream and irradiation only.</description>
    <arm_group_label>PBN-ALA-PDT Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  (1) Clinical diagnosed with AK (OLSEN classification grade I, II, III), aged &gt; 18
             years (Because no dosing or adverse event data are currently available on the use of
             topical aminolevulinic acid in patients &lt;18 years of age, children are excluded from
             this study); (2) All patients are unfit and reluctant to undergo surgery for any
             reasons, and volunteered to participate in the study and ability to understand and the
             willingness to sign a written informed consent. Patents are willing to pay for the
             treatment, and agreed to take a picture of the skin lesions.

        Exclusion Criteria:

          -  (1) Those who had ALA-PDT and any other studies that affect this study within 12 weeks
             ; (2) There are other facial diseases that may affect the efficacy evaluation, such as
             other photodermatosis; (3) Take phototoxic or photosensitizer within 8 weeks; (4)
             clinical and / or pathological prove that the tumor has invaded other organs or
             tissues; (5) Serious immunocompromised persons; (6) scar constitution; (7) Patients
             are known to have skin photosensitivity, porphyria, or allergies to ALA, light or
             lidocaine; (8) Persons are suffering from severe internal diseases, mental and mental
             illness, infectious diseases or pregnant or lactating women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiuli Wang, PhD, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Shanghai Skin Disease Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peiru Wang, PhD</last_name>
    <phone>021-18017336579</phone>
    <email>wpeiru@qq.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lude Zhu, MD</last_name>
    <phone>021-15821804557</phone>
    <email>zhulude0318@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai Dermatology Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Jingan</state>
        <zip>200443</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peiru Wang, PHD</last_name>
      <phone>021-18017336579</phone>
      <email>wpeiru@qq.com</email>
    </contact>
    <contact_backup>
      <last_name>Lude Zhu, MD</last_name>
      <phone>021-15821804557</phone>
      <email>zhulude0318@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Xiuli Wang, PHD,MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peiru Wang, PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hongwei Wang, PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kun Chen, PHD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hang Li, PHD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiaojing Kang, PHD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Xiuli Wang</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200443</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lude Zhu</last_name>
      <phone>15821804557</phone>
      <email>zhulude0318@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Peiru Wang</last_name>
      <phone>18017336579</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Pomerantz H, Hogan D, Eilers D, Swetter SM, Chen SC, Jacob SE, Warshaw EM, Stricklin G, Dellavalle RP, Sidhu-Malik N, Konnikov N, Werth VP, Keri J, Lew R, Weinstock MA; Veterans Affairs Keratinocyte Carcinoma Chemoprevention (VAKCC) Trial Group. Long-term Efficacy of Topical Fluorouracil Cream, 5%, for Treating Actinic Keratosis: A Randomized Clinical Trial. JAMA Dermatol. 2015 Sep;151(9):952-60. doi: 10.1001/jamadermatol.2015.0502.</citation>
    <PMID>25950503</PMID>
  </results_reference>
  <results_reference>
    <citation>Chen J, Zhang Y, Wang P, Wang B, Zhang G, Wang X. Plum-blossom needling promoted PpIX fluorescence intensity from 5-aminolevulinic acid in porcine skin model and patients with actnic keratosis. Photodiagnosis Photodyn Ther. 2016 Sep;15:182-90. doi: 10.1016/j.pdpdt.2016.06.012. Epub 2016 Jun 30.</citation>
    <PMID>27375183</PMID>
  </results_reference>
  <results_reference>
    <citation>Jia XH, Liu LN. [Plum blossom needling for 74 cases of scapulohumeral periarthritis]. Zhongguo Zhen Jiu. 2011 Nov;31(11):1040. Chinese.</citation>
    <PMID>22136038</PMID>
  </results_reference>
  <results_reference>
    <citation>Yao ZH, Yao XL, Wan SQ. Observation on 52 cases of paralysis of common peroneal nerve treated by acupuncture and plum-blossom needling. J Tradit Chin Med. 1984 Jun;4(2):97-100.</citation>
    <PMID>6567734</PMID>
  </results_reference>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>July 12, 2018</study_first_submitted>
  <study_first_submitted_qc>July 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2018</study_first_posted>
  <last_update_submitted>March 18, 2019</last_update_submitted>
  <last_update_submitted_qc>March 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Dermatology Hospital</investigator_affiliation>
    <investigator_full_name>Xiuli Wang</investigator_full_name>
    <investigator_title>Institute of Photomedicine</investigator_title>
  </responsible_party>
  <keyword>plum-blossom needling</keyword>
  <keyword>Photodynamic Therapy</keyword>
  <keyword>Actinic Keratoses</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratosis, Actinic</mesh_term>
    <mesh_term>Keratosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>underlie results</ipd_description>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>One year after finishing this study and for permanency</ipd_time_frame>
    <ipd_access_criteria>anyone who search pubmed</ipd_access_criteria>
    <ipd_url>http://www.ncbi.nlm.nih.gov/pubmed</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

